Edition:
United Kingdom

IRIDEX Corp (IRIX.OQ)

IRIX.OQ on NASDAQ Stock Exchange Global Market

2.00USD
16 Sep 2019
Change (% chg)

-- (--)
Prev Close
$2.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,491
52-wk High
$6.99
52-wk Low
$1.84

Summary

Name Age Since Current Position

David Bruce

59 2019 President, Chief Executive Officer, Director

Robert Grove

2018 Director

Kenneth Ludlum

64 2019 Director

Maria Sainz

53 2018 Director

Scott Shuda

53 2019 Director

Sanford Fitch

77 2004 Independent Director

Ruediger Naumann-Etienne

72 2009 Independent Director

Biographies

Name Description

David Bruce

Mr. David I. Bruce is President, Chief Executive Officer, Director of the Company. He most recently served as COO for Catheter Robotics, a privately held, commercial stage, remote catheter systems company. There he was responsible for planning and executing strategy for commercial market penetration, clinical studies and additional regulatory clearances for label expansion. Prior to that, Bruce served as President and CEO and Director of Arstasis, an arterial access device company, which he transitioned from development to commercialization and growth. Before Arstasis Bruce served as CEO and Director of Patient Safety Technologies, CEO and Director of EP MedSystems, and Platform General Manager of the AcuNav Catheter Business for Siemens Medical Solutions Ultrasound Division. Bruce began his career in engineering roles at Applied Materials and Optical Storage International. He holds a Master of Business Administration from the Wharton School at the University of Pennsylvania and a Bachelor of Science from the University of California, Berkeley.

Robert Grove

Dr. Robert Earle Grove is Director of the Company. Dr. Grove currently sits on the Nominating Committee of the American Society for Laser Medicine and Surgery and on the Scientific Advisory Board of Arbonne International. Most recently he served as Executive Chairman for the start-up ON Light Sciences, a manufacturer of transparent gel patches for accelerated tattoo removal that was acquired by Merz North America in 2016. He was co-founder of TRIA Beauty and served as that company’s Chief Executive Officer and Chief Technology Officer. Prior to TRIA Beauty, Dr. Grove co-founded Star Medical Technologies, negotiated its acquisition by Coherent and continued as president of Coherent Star. Dr. Grove’s extensive career in laser technology also included leadership roles at DermaCare, Inc., Cooper LaserSonics, Inc., and Plasma Kinetics, Inc. Grove began his career as a project leader for the Lawrence Livermore National Laboratory. He then co-founded Plasma Kinetics, which was acquired by Cooper LaserSonics. Grove continued with the company as President of the laser products division. He then co-founded DermaCare, one of the first laser med-spas in the US. Grove holds a Ph.D. in Instrumentation in the field of laser applications and an M.S. in Aeronautics and Astronautics from MIT, as well as a B.S.in Engineering Physics from Cornell University.

Kenneth Ludlum

Mr. Kenneth E. Ludlum is Director of the company. Ludlum also served as Chief Financial Officer of CareDx, a molecular diagnostics company, through the company's initial public offering in 2014. Prior to that, he served in executive roles at two medical device companies, including President and CEO of Revivant Corporation and CFO of Perclose Inc. Prior to 25 years in operating positions, Ludlum spent 10 years as an investment banker, primarily with Montgomery Securities.

Maria Sainz

Ms. Maria Degois Sainz is Director of the IRIDEX CORPORATIONShe brings 25 years of experience in the medical device industry to the IRIDEX Board of Directors. Sainz most recently served as President and Chief Executive Officer of CardioKinetix, a privately held transcatheter cardiovascular implant company. There she led the company's regulatory, clinical and commercialization efforts outside the U.S. while securing expedited access pathway status for the device in the U.S. Previously she served as President and CEO for Concentric Medical where she contributed to ramping revenues to $36 million and negotiated the acquisition of the company by Stryker Corporation. Prior, Sainz held several leadership positions with Guidant Corporation. She was President of the Cardiac Surgery Division for Guidant at the time of the company's acquisition by Boston Scientific, at which point she continued as an advisor to Boston Scientific. Sainz began her career at Eli Lilly & Co. She holds a Master of Arts in Languages from the University of Complutense in Madrid and a Master of International Management from the American Graduate School of International Management. She currently serves on the Board of Directors for Halyard Health, Orthofix International and MRI Interventions.

Scott Shuda

Mr. Scott A. Shuda is Director of Iridex Corp. Mr. Shuda is the Managing Director and Co-founder of BlueLine Partners, LLC, an investment firm that focuses on publicly listed technology and healthcare companies. Mr. Shuda served as a director and Audit Committee member of MGC Diagnostics Corporation (formerly Angeion Corporation), a global medical technology company from 2010 to 2011. Prior to co-founding BlueLine Partners in April 2004, Mr. Shuda was General Counsel to Vicinity Corporation, an internet search company that went public in 2000 and was acquired by Microsoft in 2002. Prior to his employment with Vicinity, Mr. Shuda practiced law in California and New York, most recently in the Silicon Valley office of Latham & Watkins LLP. Mr. Shuda holds a J.D. from Georgetown University and an M.B.A. from Georgetown University. Mr. Shuda is independent and has extensive experience with the medical devices industry. He brings more than a decade of professional experience in law, technology and entrepreneurial endeavors in the industry, including transactions that range from initial public offerings and venture financings to mergers and acquisitions. Mr. Shuda’s background as a corporate finance attorney, general counsel of a public company, and managing director of a private investment fund focusing on healthcare companies provides the Company with a strong perspective on the capital markets, a deep understanding of the challenges facing small public companies and the perspective of our stockholders. Mr. Shuda’s education and experience have provided

Sanford Fitch

Mr. Sanford Fitch is Independent Director of Iridex Corp., since April 7, 2004. Mr. Fitch has served as a director and Audit Committee Chairman of Masimo Corp, a public company that designs, develops, manufactures and sells medical devices, since November 2006. Mr. Fitch also currently serves as a director of Ozone International, Inc., a privately held technology company. Mr. Fitch served as a director and Audit Committee Chairman of Foxhollow Technologies, Inc., a public company that designed, developed, manufactured and sold medical devices, from June 2004 until October 2007. He also served as a director and Audit Committee Chairman of Conceptus Inc., a public medical device company, from December 1994 until April 2004. Mr. Fitch was Chief Financial Officer and Senior Vice President of Operations of Conceptus from December 1994 through October 1998 and took the company public in 1996. Mr. Fitch also served as Chief Financial Officer of several start-up technology companies from 1998 until 2002. From December 1990 to January 1994, Mr. Fitch served as Chief Financial Officer of SanDisk Corp., a manufacturer of flash memory devices. From 1983 through 1989, Mr. Fitch was the Chief Financial Officer of Komag Inc., a manufacturer of rigid thin film media for the disk drive industry, and took the company public in 1987. Mr. Fitch holds a B.S. in Chemistry and an M.B.A. from Stanford University. Mr. Fitch is independent and has extensive experience in the medical device industry. Mr. Fitch’s executive management and past board service have provided him with leadership and technical skills to firmly understand IRIDEX’s business.

Ruediger Naumann-Etienne

Dr. Ruediger Naumann-Etienne Ph.D. is Independent Director of Iridex Corp., since December 18, 2009. Dr. Naumann-Etienne has been the owner and Managing Director of Intertec Group, an investment company specializing in the medical device field, since 1989. He was Chairman of Cardiac Science Corporation from 2006 until the company was sold to Opto Electronics of India in 2010. From 2000 to 2005, Dr. Naumann-Etienne served as Chairman and from 2000 to 2003 as Chief Executive Officer of Quinton Cardiology Systems, one of the predecessor companies of Cardiac Science. From 1993 until 1999, Dr. Naumann-Etienne was Chairman of OEC Medical Systems, a manufacturer of fluoroscopic imaging systems and from 1987 to 1990 he was President and Chief Operating Officer of Diasonics, a manufacturer of diagnostic imaging equipment. Dr. Naumann-Etienne has served on the board of directors of Varian Medical Systems, Inc., a public medical device company, since 2003, and Encision Inc., a public medical device company, since October 2008. Dr. Naumann-Etienne also served as a director of Cardiac Science Corporation, a public medical device company, from September 2005 until December 2010, and Bio-Rad Laboratories, Inc., a public life science company, from October 2003 until December 2009. Dr. Naumann-Etienne holds a Ph.D. in International Finance from the University of Michigan. He holds a Master’s Degree in Industrial Management from the Georgia Institute of Technology and holds an undergraduate degree in Business Administration from the Technical University Berlin, Germany.